This is in line with findings in moderate breast cancer risk genes such as CHEK2, PALB2 and ATM [44–46] and suggests that PRS inclusion in risk stratification may in particular be relevant to prevent excess of surveillance measures in PV carriers of those genes. This evidence concerns the gene CHEK2 and breast cancer.